Frontiers in Oncology (Nov 2021)
Biological Rationale and Clinical Evidence of Carbon Ion Radiation Therapy for Adenoid Cystic Carcinoma: A Narrative Review
- Pierre Loap,
- Pierre Loap,
- Pierre Loap,
- Barbara Vischioni,
- Maria Bonora,
- Rossana Ingargiola,
- Sara Ronchi,
- Viviana Vitolo,
- Amelia Barcellini,
- Lucia Goanta,
- Ludovic De Marzi,
- Ludovic De Marzi,
- Ludovic De Marzi,
- Remi Dendale,
- Remi Dendale,
- Roberto Pacelli,
- Laura Locati,
- Laura Locati,
- Valentin Calugaru,
- Valentin Calugaru,
- Hamid Mammar,
- Hamid Mammar,
- Stefano Cavalieri,
- Stefano Cavalieri,
- Youlia Kirova,
- Youlia Kirova,
- Ester Orlandi
Affiliations
- Pierre Loap
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
- Pierre Loap
- Department of Radiation Oncology, Institut Curie, Paris, France
- Pierre Loap
- Proton Therapy Center, Institut Curie, Orsay, France
- Barbara Vischioni
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
- Maria Bonora
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
- Rossana Ingargiola
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
- Sara Ronchi
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
- Viviana Vitolo
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
- Amelia Barcellini
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
- Lucia Goanta
- Department of Advanced Biomedical Sciences, University of Naples “Federico II”, Napoli, Italy
- Ludovic De Marzi
- Department of Radiation Oncology, Institut Curie, Paris, France
- Ludovic De Marzi
- Proton Therapy Center, Institut Curie, Orsay, France
- Ludovic De Marzi
- Institut Curie, PSL Research University, University Paris Saclay, INSERM LITO, Orsay, France
- Remi Dendale
- Department of Radiation Oncology, Institut Curie, Paris, France
- Remi Dendale
- Proton Therapy Center, Institut Curie, Orsay, France
- Roberto Pacelli
- Department of Advanced Biomedical Sciences, University of Naples “Federico II”, Napoli, Italy
- Laura Locati
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Laura Locati
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Valentin Calugaru
- Department of Radiation Oncology, Institut Curie, Paris, France
- Valentin Calugaru
- Proton Therapy Center, Institut Curie, Orsay, France
- Hamid Mammar
- Department of Radiation Oncology, Institut Curie, Paris, France
- Hamid Mammar
- Proton Therapy Center, Institut Curie, Orsay, France
- Stefano Cavalieri
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Stefano Cavalieri
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Youlia Kirova
- Department of Radiation Oncology, Institut Curie, Paris, France
- Youlia Kirova
- Proton Therapy Center, Institut Curie, Orsay, France
- Ester Orlandi
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
- DOI
- https://doi.org/10.3389/fonc.2021.789079
- Journal volume & issue
-
Vol. 11
Abstract
Adenoid cystic carcinoma (ACC) is a rare, basaloid, epithelial tumor, arising mostly from salivary glands. Radiation therapy can be employed as a single modality for unresectable tumors, in an adjuvant setting after uncomplete resection, in case of high-risk pathological features, or for recurrent tumors. Due to ACC intrinsic radioresistance, high linear energy transfer (LET) radiotherapy techniques have been evaluated for ACC irradiation: while fast neutron therapy has now been abandoned due to toxicity concerns, charged particle beams such as protons and carbon ions are at present the beams used for hadron therapy. Carbon ion radiation therapy (CIRT) is currently increasingly used for ACC irradiation. The aim of this review is to describe the immunological, molecular and clinicopathological bases that support ACC treatment with CIRT, as well as to expose the current clinical evidence that reveal the advantages of using CIRT for treating ACC.
Keywords
- adenoid cyst carcinoma
- hadrontherapy
- carbon ion radiotherapy (CIRT)
- tumor immunology
- radioresistance
